Surgery
Volume 146, Issue 2 , Pages 316-324 , August 2009

Daptomycin for the treatment of surgical site infections

  • Ronald S. Chamberlain, MD, MPA

      Affiliations

    • Department of Surgery, St Barnabas Medical Center, Livingston, NJ
    • Corresponding Author InformationReprint requests: Ronald S. Chamberlain, MD, MPA, Department of Surgery, St Barnabas Medical Center, Department of Surgery, 94 Old Short Hills Road, Livingston, NJ 07039.
    • ,
  • Darren L. Culshaw, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, MA
    • ,
  • Brian J. Donovan, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, MA
    • ,
  • Kenneth C. Lamp, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, MA

,Accepted 20 March 2009.

References 

  1. Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007;122:160–166
  2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control. 2002;30:458–475
  3. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:458–485
  4. Bratzler DW, Houck PM, Richards C, Steele L, Dellinger EP, Fry DE, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg. 2005;140:174–182
  5. Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol. 1999;20:725–730
  6. Kaye KS, Schmader KE, Sawyer R. Surgical site infection in the elderly population. Clin Infect Dis. 2004;39:1835–1841
  7. Petti CA, Sanders LL, Trivette SL, Briggs J, Sexton DJ. Postoperative bacteremia secondary to surgical site infection. Clin Infect Dis. 2002;34:305–308
  8. Lodise TP, McKinnon PS, Swiderski L, Ryback MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36:1418–1423
  9. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592–598
  10. Cantlon CA, Stemper ME, Schwan WR, Hoffman MA, Qutaishat SS. Significant pathogens isolated from surgical site infections at a community hospital in the Midwest. Am J Infect Control. 2006;34:526–529
  11. Patel M, Kumar RA, Stamm AM, Hoesley CJ, Moser SA, Waites KB. USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J Clin Microbiol. 2007;45:3431–3433
  12. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?. Clin Infect Dis. 2008;46:787–794
  13. Manian FA, Griesnauer S. Community-associated methicillin-resistant Staphylococcus aureus (MRSA) is replacing traditional health care-associated MRSA strains in surgical-site infections among inpatients. Clin Infect Dis. 2008;47:434–435
  14. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352:1445–1453
  15. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883–3886
  16. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother. 2007;60:788–794
  17. Cubicin [prescribing information]. Lexington, Mass: Cubist Pharmaceuticals; 2007;
  18. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681
  19. Knapp AG, Kamepalli RK, Martone WJ, Yankelev S. A prospective, comparative study of daptomycin for the treatment of superficial and deep surgical site infections. Presented at: 26th Annual Meeting of the Surgical Infection Society, April 27–29, 2006, San Diego, CA.
  20. Rolston KVI, Segreti JA, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (COREsm) methodology. Am J Med. 2007;120:S4–S5
  21. Forrest GN, Donovan BJ, Lamp KC, Friedrich LV. Clinical experience with daptomycin for the treatment of patients with documented Gram-positive septic arthritis. Ann Pharmacother. 2008;42:213–217
  22. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007;28:1047–1053
  23. Gonzalez BE, Rueda AM. Shelburne SA III, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol. 2006;27:1051–1056
  24. Davis SL, Perri MB, Donabedian SM, Manierski C, Singh A, Vager D, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol. 2007;45:1705–1711
  25. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144:309–317
  26. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg. 2004;188:760–766
  27. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A. 2007;104:9451–9456
  28. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP. Penetration of daptomycin into soft tissues in diabetic versus healthy volunteers by in vivo microdialysis. Antimicrob Agents Chemother. 2008;52:3941–3946
  29. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother. 2002;46:31–33

 An abstract on this subject was accepted for a 3-minute oral presentation at 4th Annual Academic Surgical Congress, Fort Myers, Florida, February 3–6, 2009.

 Dr Chamberlain is associated with Cubist (speaker's bureau), Ethicon (scientific advisor), Pfizer (speaker's bureau), and Wyeth (speaker's bureau). Messrs Culshaw, Donovan, and Lamp are employees of Cubist.

PII: S0039-6060(09)00271-2

doi: 10.1016/j.surg.2009.03.037

Surgery
Volume 146, Issue 2 , Pages 316-324 , August 2009

Article Tools